Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2selinexor 1ponatinib 1poly ICLC 1pemigatinib 1neratinib 1donafenib 1cobimetinib 1ceritinib 1cemiplimab 1brigatinib 1abemaciclib 1Thymopentin 1Taxes 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Radiation 1Pluvicto 1Platinum Compounds 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Neck Dissection 1NF protocol 1Magnetic Resonance Spectroscopy 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma × pemigatinib × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡